SCHEMBL4330116

SCHEMBL4330116

CN(C)C(=O)c1c[c]cc(Cl)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.38
HPGD P15428 4/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
SLC6A2 P23975 3/20 0.37
SLC6A4 P31645 3/20 0.37
SLC6A3 Q01959 2/20 0.37
KCNH2 Q12809 1/20 0.36
PKM P14618 1/20 0.36
MALT1 Q9UDY8 1/20 0.36
TPMT P51580 1/20 0.35
HTT P42858 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
GAA P10253 2/20 0.34
MAPT P10636 2/20 0.34
GFER P55789 1/20 0.34
ERN1 O75460 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4316036 0.87 SMN1; SMN2 (0.43) ALDH1A1HPGDSMN1; SMN2SLC6A2SLC6A4
SCHEMBL4324742 0.80 ALDH1A1 (0.38) ALDH1A1HPGDSMN1; SMN2ERN1
SCHEMBL4328710 0.80 ALDH1A1 (0.38) ALDH1A1HPGDSMN1; SMN2TPMTERN1
SCHEMBL160446 0.79 HSP90AA1 (0.50) ALDH1A1HPGDSMN1; SMN2MAPTMEN1
SCHEMBL3784787 0.79 TPMT (0.46) ALDH1A1HPGDSMN1; SMN2SLC6A2SLC6A4
SCHEMBL1004039 0.79 TPMT (0.52) ALDH1A1HPGDSMN1; SMN2SLC6A2SLC6A4
SCHEMBL4691359 0.78 SMN1; SMN2 (0.37) ALDH1A1HPGDSMN1; SMN2HTTNPC1
SCHEMBL4317908 0.78 ALDH1A1 (0.37) ALDH1A1HPGDSMN1; SMN2MAPTERN1
SCHEMBL5944061 0.76 MAPT (0.48) ALDH1A1SMN1; SMN2HTTNPC1RAB9A
SCHEMBL4319254 0.76 PDK1 (0.36) ALDH1A1HPGDSMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2042502-A1 Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor JAPAN TOBACCO INC. (JP) 2009-04-01 EP disclosed
EP-1544199-B1 NITROGENOUS CONDENSED-RING COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR JAPAN TOBACCO INC (JP) 2008-10-15 EP disclosed
US-20080161311-A1 Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor JAPAN TOBACCO INC. 2008-07-03 US disclosed
US-7211572-B2 Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor JAPAN TOBACCO INC. (JP) 2007-05-01 US disclosed
US-20060052361-A1 Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor JAPAN TOBACCO INC. 2006-03-09 US disclosed
EP-1544199-A1 NITROGENOUS CONDENSED-RING COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR JAPAN TOBACCO INC. (JP) 2005-06-22 EP disclosed
US-20050054645-A1 Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor JAPAN TOBACCO INC. (JP) 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054645-A1 Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor NNMT, PNP, DNTT ALDH1A1 2068/4885HPGD 1768/4885SMN1; SMN2 2501/4885
US-20060052361-A1 Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor NNMT, PNP, DNTT ALDH1A1 2068/4885HPGD 1768/4885SMN1; SMN2 2501/4885
US-20080161311-A1 Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor DNTT, PNP, NNMT ALDH1A1 1706/4885HPGD 1295/4885SMN1; SMN2 2251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.